Welcome to our dedicated page for TransMedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TransMedics Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TransMedics Group's regulatory disclosures and financial reporting.
TransMedics Group, Inc. explains how releasing a U.S. tax valuation allowance changed its previously reported fourth-quarter 2025 results. In Q4 2025 the company released a $103.3 million valuation allowance on deferred tax assets, creating a net income tax benefit of $83.8 million and driving a reported annual effective tax rate of (77.0)%.
For Q4 2025, income before income taxes was $21.6 million. Reported net income was $105.4 million, or $2.62 per diluted share. Using a 19.1% annual effective tax rate excluding the allowance release, adjusted Q4 net income is $17.5 million, or $0.47 per diluted share. The company expects future quarterly tax provisions to align more closely with typical U.S. corporate tax rates.
TransMedics Group, Inc. presents its annual report describing a fast-growing medical technology business built around its Organ Care System (OCS) and National OCS Program (NOP) for heart, lung and liver transplantation.
The company generated $605.5 million of revenue in 2025, up from $441.5 million in 2024 and $241.6 million in 2023, reflecting strong adoption of its single-use disposables and NOP services. TransMedics operates 22 fixed‑wing aircraft, is developing next‑generation and Gen‑3 OCS platforms including OCS Kidney, and is expanding logistics and R&D infrastructure in the U.S. and Europe.
The filing highlights extensive clinical evidence and a large patent portfolio but also notes risks such as fluctuating results, dependence on OCS and NOP, identified material weakness in internal controls, reimbursement dynamics, supply chain reliance, and the need for additional funding and debt service on 1.50% convertible notes due 2028.
TransMedics Group, Inc. reported strong growth for the fourth quarter and full year 2025, driven by broader use of its Organ Care System and related services. Fourth quarter revenue reached $160.8 million, up 32% year over year, while full year 2025 revenue rose to $605.5 million, a 37% increase.
Net income jumped to $105.4 million in the fourth quarter and $190.3 million for the full year, helped by a one-time tax benefit from releasing a valuation allowance on deferred tax assets. The company maintained gross margins around 58–60% and increased investment in research, clinical programs, and commercial infrastructure.
TransMedics completed 5,139 U.S. NOP cases in 2025, expanded its owned aviation fleet to 22 aircraft, and received FDA approval for key heart and lung trials. For 2026, it projects revenue between $727 million and $757 million, implying 20% to 25% growth over 2025.
TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.
The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.
TransMedics Group, Inc. filed an amended insider ownership report for Chief Commercial Officer Giovanni Cecere. The filing shows he beneficially holds 7,975 restricted stock units (RSUs), each representing a contingent right to receive one share of TransMedics common stock.
These RSUs are reported as directly owned and reflect an equity award rather than an open-market stock purchase or sale. The disclosure updates the market on Cecere’s initial equity-based holdings in the company.
TransMedics Group, Inc. filed an initial ownership report for executive Giovanni Cecere, who serves as Chief Commercial Officer. This Form 3 states that no securities are beneficially owned, meaning Cecere reports holding no TransMedics Group stock or derivative securities as of the event date.
TransMedics Group, Inc. announced leadership transitions in its commercial and legal functions. The Board appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, M.D., who will become Senior Vice President of International on the same date.
The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 or his actual start date. Current General Counsel Anil Ranganath will move to a non-executive employee role until June 7, 2026 and then serve as a non-employee consultant until September 7, 2026. His equity awards will continue to vest during his service, and he will receive an annualized consultant fee of $10,000, plus cash severance equal to 0.75 times his highest recent base salary and bonus, COBRA premiums for up to nine months, and a pro-rated 2026 bonus, subject to a release of claims and ongoing covenants.